PHOENIX, Ariz. — Oct. 4, 2012 — Dr. Daniel Von Hoff, Physician-In-Chief of the Translational Genomics Research Institute (TGen), is the first recipient of the Lori Groetken Memorial Lecture and Award.
Dr. Von Hoff's lecture, "A Relentless Molecular Pursuit Approach to Take Out Pancreatic Cancer," is at noon Oct. 5 at the Siteman Cancer Center at Washington University in St. Louis.
"I am extremely honored and humbled to be the first recipient of the Lori Groetken Memorial Lecture, and I look forward to the opportunity to present this lecture and discuss how we can make advances together against this terrible cancer," said Dr. Von Hoff.
The lecture and award is in memory of Lori Groetken, a pancreatic cancer patient who fought the disease for two years. She and her husband, Cecil, were at the forefront of raising funds for pancreatic cancer research at the Siteman Cancer Center. The annual lecture series in her name has been created to recognize individuals whose research makes substantial contributions to the field of pancreatic cancer research.
"In light of your significant contributions in leading the world efforts in genomic research and novel therapy development in pancreatic cancer research, you have been selected to be the inaugural recipient for the Lori (Groetken) Memorial Lectureship," according to a letter to Dr. Von Hoff from Dr. Andrea Wang-Gillam, Assistant Professor in the Division of Oncology, Section of Medical Oncology, at Washington University.
Dr. Von Hoff, M.D., F.A.C.P., is an internationally recognized physician-scientist who has contributed to the development of numerous anticancer agents, including paclitaxel, docetaxel, irinotecan and gemcitabine. He also is the Chief Scientific Officer of TGen's clinical trials at Scottsdale Healthcare's Virginia G. Piper Cancer Center, Chief Scientific Officer at US Oncology, Professor of Medicine at Mayo Clinic, and Clinical Professor of Medicine at the University of Arizona College of Medicine.
A book published this year — The Creative Destruction of Medicine by Dr. Eric Topol, Director of the Scripps Translational Science Institute — describes Dr. Von Hoff as the nation's "leading authority on pancreatic cancer."
In 2010, Dr. Von Hoff won a top award from the American Society of Clinical Oncology (ASCO) for his cancer research. He received the David A. Karnofsky Memorial Award and Lecture at ASCO's 46th Annual Meeting "for his outstanding achievements in cancer research and for his impact on the treatment of patients with cancer."
Dr. Von Hoff is the Co-Team Leader for the Stand Up To Cancer (SU2C) Pancreatic Cancer "Dream Team," in which he leads a team investigating how to cut off the fuel supply of nutrients to pancreatic cancer cells.
Dr. Von Hoff founded the Pancreatic Cancer Research Team (PCRT), an international network of clinical trials sites organized under TGen Drug Development (TD2), a TGen subsidiary. PCRT represents a consortium of 45 highly experienced investigators and clinics from across the U.S. and Europe, dedicated to finding a cure for pancreatic cancer, which annually kills more than 37,000 people in the U.S., and is the nation's 4th leading cause of cancer death.
The Translational Genomics Research Institute (TGen) is a Phoenix-based non-profit organization dedicated to conducting groundbreaking research with life changing results. Research at TGen is focused on helping patients with diseases such as cancer, neurological disorders and diabetes. TGen is on the cutting edge of translational research where investigators are able to unravel the genetic components of common and complex diseases. Working with collaborators in the scientific and medical communities, TGen believes it can make a substantial contribution to the efficiency and effectiveness of the translational process. For more information, visit: www.tgen.org.
TGen Senior Science Writer
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.